Advertisement

Current Hepatology Reports

, Volume 18, Issue 3, pp 322–330 | Cite as

Epidemiology, Diagnosis, and Management of Bone Disease in Patients with Chronic HBV Infection

  • Mike T. Wei
  • Mindie H. Nguyen
  • Ramsey CheungEmail author
Hepatitis B (JK Lim, Section Editor)
  • 22 Downloads
Part of the following topical collections:
  1. Topical Collection on Hepatitis B

Abstract

Purpose of Review

Chronic hepatitis B (CHB) and treatment may be associated with increased risk of osteopenia/osteoporosis. Here, we review the prevalence of osteopenia/osteoporosis among patients with CHB and the effect of antiviral therapy on bone density. We also highlight screening and management strategies for bone disease among patients with CHB.

Recent Findings

While there are concerns with first-line antiviral therapy such as tenofovir disoproxil fumarate in the development of osteopenia/osteoporosis, the available data remain rather unclear. However, with the development of tenofovir alafenamide, these concerns may be mitigated. At present, EASL recommends dual-energy X-ray absorption (DEXA) scans for patients with osteoporotic risk factors, with a repeat DEXA scan based upon baseline findings.

Summary

Patients with CHB have higher incidence and prevalence of osteopenia/osteoporosis compared with patients without CHB. Further studies are needed to understand the impact of antiviral therapy on bone therapy, and more CHB specific recommendations are needed for bone health management.

Keywords

Hepatitis B Tenofovir disoproxil fumarate Entecavir Osteoporosis Tenofovir alafenamide 

Notes

Compliance with Ethical Standards

Conflict of Interest

Mike T. Wei declares no potential conflict of interest. Mindie H. Nguyen received research support from Pfizer, Gilead Sciences, Janssen, Exact Sciences, Bristol-Myers Squibb, and Laboratory of Advanced Medicine and served as an advisory board member for Bristol-Myers Squibb, Gilead Sciences, Roche, Janssen, Novartis, Intercept, Anylam, Spring Bank, Bayer, Exact Sciences, Laboratory of Advanced Medicine, Eisai, and Dynavax. Dr. Nguyen also reports grants from Bristol-Myers Squibb, Janssen Pharmaceuticals, Gilead Sciences, NCI, and B. K. Kee Foundation and reports honorarium from Bristol-Myers Squibb, Gilead Sciences, Intercept Pharmaceuticals, Roche Laboratories, Dynavax Laboratory, and Alnylam Pharmaceuticals. Ramsey Cheung reports grants from Gilead Science, outside the submitted work.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    MacLachlan JH, Locarnini S, Cowie BC. Estimating the global prevalence of hepatitis B. Lancet. 2015;386(10003):1515–7.  https://doi.org/10.1016/S0140-6736(15)61116-3.CrossRefPubMedGoogle Scholar
  2. 2.
    World Health Organization. Hepatitis B. http://www.who.int/mediacentre/factsheets/fs204/en/. 2017.
  3. 3.
    Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546–55.  https://doi.org/10.1016/S0140-6736(15)61412-X.CrossRefPubMedGoogle Scholar
  4. 4.
    Tang LSY, Covert E, Wilson E, Kottilil S. Chronic hepatitis B infection: a review. JAMA. 2018;319(17):1802–13.  https://doi.org/10.1001/jama.2018.3795.CrossRefPubMedGoogle Scholar
  5. 5.
    • National Institutes of Health. Osteoporosis overview. https://www.bones.nih.gov/health-info/bone/osteoporosis/overview. an on-line overview on the topic.
  6. 6.
    Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016;22(Suppl 4):1–42.  https://doi.org/10.4158/EP161435.GL.CrossRefPubMedGoogle Scholar
  7. 7.
    World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. 2007.Google Scholar
  8. 8.
    Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.  https://doi.org/10.1007/s00198-014-2794-2.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–6.  https://doi.org/10.1002/jbmr.2269.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Guarino M, Loperto I, Camera S, Cossiga V, Di Somma C, Colao A, et al. Osteoporosis across chronic liver disease. Osteoporos Int. 2016;27(6):1967–77.  https://doi.org/10.1007/s00198-016-3512-z.CrossRefPubMedGoogle Scholar
  11. 11.
    Wariaghli G, Mounach A, Achemlal L, Benbaghdadi I, Aouragh A, Bezza A, et al. Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int. 2010;30(7):893–9.  https://doi.org/10.1007/s00296-009-1071-8.CrossRefPubMedGoogle Scholar
  12. 12.
    Leslie WD, Bernstein CN, Leboff MS, Commitee AGACP. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology. 2003;125(3):941–66.CrossRefGoogle Scholar
  13. 13.
    Baeg MK, Yoon SK, Ko SH, Han KD, Choi HJ, Bae SH, et al. Males seropositive for hepatitis B surface antigen are at risk of lower bone mineral density: the 2008-2010 Korea National Health and Nutrition Examination Surveys. Hepatol Int. 2016;10(3):470–7.  https://doi.org/10.1007/s12072-015-9672-7.CrossRefPubMedGoogle Scholar
  14. 14.
    Collier J. Bone disorders in chronic liver disease. Hepatology. 2007;46(4):1271–8.  https://doi.org/10.1002/hep.21852.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen CH, Lin CL, Kao CH. Association between chronic hepatitis B virus infection and risk of osteoporosis: a nationwide population-based study. Medicine (Baltimore). 2015;94(50):e2276.  https://doi.org/10.1097/MD.0000000000002276.CrossRefGoogle Scholar
  16. 16.
    Gallego-Rojo FJ, Gonzalez-Calvin JL, Muñoz-Torres M, Mundi JL, Fernandez-Perez R, Rodrigo-Moreno D. Bone mineral density, serum insulin-like growth factor I, and bone turnover markers in viral cirrhosis. Hepatology. 1998;28(3):695–9.  https://doi.org/10.1002/hep.510280315.CrossRefPubMedGoogle Scholar
  17. 17.
    Tien C, Xu JJ, Chan LS, Chang M, Lim C, Lee S, et al. Long-term treatment with tenofovir in Asian-American chronic hepatitis B patients is associated with abnormal renal phosphate handling. Dig Dis Sci. 2015;60(2):566–72.  https://doi.org/10.1007/s10620-014-3363-4.CrossRefPubMedGoogle Scholar
  18. 18.
    • Nguyen MH, Lim JK, Ozbay AB, Fraysse J, Liou I, Meyer N, et al. Advancing age and comorbidity in a United States insured population-based cohort of patients with chronic hepatitis B. Hepatology. 2018.  https://doi.org/10.1002/hep.30246 large population-based study from the U.S.
  19. 19.
    Liu A, Le A, Zhang J, Wong C, Henry L, Nguyen MH. Increasing co-morbidities in chronic hepatitis B patients: experience in primary care and referral practices during 2000-2015. Clin Transl Gastroenterol. 2018;9(3):141.  https://doi.org/10.1038/s41424-018-0007-6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Wei MT, Le AK, Chang MS, Hsu H, Nguyen P, Zhang JQ, et al. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. J Med Virol. 2019;91:1288–94.  https://doi.org/10.1002/jmv.25433.CrossRefPubMedGoogle Scholar
  21. 21.
    • European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.  https://doi.org/10.1016/j.jhep.2017.03.021. Practice guidelines on management of chronic hepatitis B.
  22. 22.
    • Terrault NA, Lok AS, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018.  https://doi.org/10.1002/hep.29800 Practice guidelines on management of chronic hepatitis B.
  23. 23.
    Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10(1):1–98.  https://doi.org/10.1007/s12072-015-9675-4.CrossRefPubMedGoogle Scholar
  24. 24.
    Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJ, Barr DA, et al. Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? J Infect Dis. 2015;211(3):374–82.  https://doi.org/10.1093/infdis/jiu471.CrossRefPubMedGoogle Scholar
  25. 25.
    Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201.  https://doi.org/10.1001/jama.292.2.191.CrossRefPubMedGoogle Scholar
  26. 26.
    Martin A, Bloch M, Amin J, Baker D, Cooper DA, Emery S, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial. Clin Infect Dis. 2009;49(10):1591–601.  https://doi.org/10.1086/644769.CrossRefPubMedGoogle Scholar
  27. 27.
    Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51(8):963–72.  https://doi.org/10.1086/656417.CrossRefPubMedGoogle Scholar
  28. 28.
    Hsu YC, Wei MT, Nguyen MH. Tenofovir alafenamide as compared to tenofovir disoproxil fumarate in the management of chronic hepatitis B with recent trends in patient demographics. Expert Rev Gastroenterol Hepatol. 2017;11(11):999–1008.  https://doi.org/10.1080/17474124.2017.1386554.CrossRefPubMedGoogle Scholar
  29. 29.
    Fung J, Seto WK, Lai CL, Yuen MF. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol. 2014;29(3):428–34.  https://doi.org/10.1111/jgh.12499.CrossRefPubMedGoogle Scholar
  30. 30.
    Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60(5):1457–64.  https://doi.org/10.1007/s10620-014-3486-7.CrossRefPubMedGoogle Scholar
  31. 31.
    Fung S, Kwan P, Fabri M, Horban A, Pelemis M, Hann HW, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146(4):980–8.  https://doi.org/10.1053/j.gastro.2013.12.028.CrossRefPubMedGoogle Scholar
  32. 32.
    Maggi P, Montinaro V, Leone A, Fasano M, Volpe A, Bellacosa C, et al. Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. J Antimicrob Chemother. 2015;70(4):1150–4.  https://doi.org/10.1093/jac/dku502.CrossRefPubMedGoogle Scholar
  33. 33.
    Wong GL, Tse YK, Wong VW, Yip TC, Tsoi KK, Chan HL. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: a cohort study of 53,500 subjects. Hepatology. 2015;62(3):684–93.  https://doi.org/10.1002/hep.27894.CrossRefPubMedGoogle Scholar
  34. 34.
    Bunchorntavakul C, Taweewattanakitbavorn V, Atsawarungruangkit A. Bone mineral density and renal function in chronic hepatitis B patients receiving nucleotide versus nucleoside analogs: a pilot prospective study. J Med Assoc Thail. 2016;99(Suppl 2):S1–8.Google Scholar
  35. 35.
    Saeedi R, Mojebi-Mogharar A, Sandhu SK, Dubland JA, Ford JA, Yousefi M, et al. Lamivudine, entecavir, or tenofovir treatment of hepatitis B infection: effects on calcium, phosphate, FGF23 and indicators of bone metabolism. Ann Hepatol. 2017;16(2):207–14.  https://doi.org/10.5604/16652681.1231577.CrossRefPubMedGoogle Scholar
  36. 36.
    Tonon M, Piano S, Romano A, Fasolato S, Stanco M, Pilutti C, et al. Assessment of bone mineral density in patients with cirrhosis treated with third-generation nucleos(t)ide analogues: comparison between tenofovir and entecavir. Eur J Gastroenterol Hepatol. 2018:1.  https://doi.org/10.1097/MEG.0000000000001051.
  37. 37.
    Ruane PJ, DeJesus E, Berger D, Markowitz M, Bredeek UF, Callebaut C, et al. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults. J Acquir Immune Defic Syndr. 2013;63(4):449–55.  https://doi.org/10.1097/QAI.0b013e3182965d45.CrossRefPubMedGoogle Scholar
  38. 38.
    Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol. 2015;62(3):533–40.  https://doi.org/10.1016/j.jhep.2014.10.035.CrossRefPubMedGoogle Scholar
  39. 39.
    Wei MT, Le AK, Chang MS, Hsu Y-C, Nguyen P, Zhang JQ et al. Antiviral therapy and the development of osteopenia/osteoporosis among Asians with chronic hepatitis B. 2018.Google Scholar
  40. 40.
    •• Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196–206.  https://doi.org/10.1016/S2468-1253(16)30107-8 Tenofovir alafenamide clinical trial. CrossRefPubMedGoogle Scholar
  41. 41.
    •• Chan HL, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–95.  https://doi.org/10.1016/S2468-1253(16)30024-3 Tenofovir alafenamide clinical trial. CrossRefPubMedGoogle Scholar
  42. 42.
    Seto WK, Asahina Y, Brown TT, Peng CY, Stanciu C, Abdurakhmanov D, et al. Improved bone safety of tenofovir alafenamide compared to tenofovir disoproxil fumarate over 2 years in patients with chronic HBV infection. Clin Gastroenterol Hepatol. 2018.  https://doi.org/10.1016/j.cgh.2018.06.023.
  43. 43.
    Li J, Chang MS, Tran TT, Nguyen MH. Management of chronic hepatitis B in pregnancy. J Clin Gastroenterol. 2017;51(9):789–95.  https://doi.org/10.1097/MCG.0000000000000908.CrossRefPubMedGoogle Scholar
  44. 44.
    Collier JD, Ninkovic M, Compston JE. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut. 2002;50(Suppl 1):i1–9.CrossRefGoogle Scholar
  45. 45.
    •• European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease. J Hepatol. 2019;70(1):172–93.  https://doi.org/10.1016/j.jhep.2018.06.024. EASL guidelines on bone disease and management in patient with chronic liver disease.
  46. 46.
    Chaney A, Heckman MG, Diehl NN, Meek S, Keaveny AP. Effectiveness and outcomes of current practice in treating vitamin D deficiency in patients listed for liver transplantation. Endocr Pract. 2015;21(7):761–9.  https://doi.org/10.4158/EP14416.OR.CrossRefPubMedGoogle Scholar
  47. 47.
    Ensrud KE, Crandall CJ. Osteoporosis. Ann Intern Med. 2017;167(3):ITC17–32.  https://doi.org/10.7326/AITC201708010.CrossRefGoogle Scholar
  48. 48.
    • Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for osteoporosis to prevent fractures: US preventive services task force recommendation statement. JAMA. 2018;319(24):2521–31.  https://doi.org/10.1001/jama.2018.7498 General recommendation on screening for osteoporosis. CrossRefPubMedGoogle Scholar
  49. 49.
    Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, et al. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. Hepatology. 2005;42(4):762–71.  https://doi.org/10.1002/hep.20866.CrossRefPubMedGoogle Scholar
  50. 50.
    Guañabens N, Parés A, Ros I, Alvarez L, Pons F, Caballería L, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98(10):2268–74.  https://doi.org/10.1111/j.1572-0241.2003.07639.x.CrossRefPubMedGoogle Scholar
  51. 51.
    Yurci A, Kalkan AO, Ozbakir O, Karaman A, Torun E, Kula M, et al. Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease. Eur J Gastroenterol Hepatol. 2011;23(12):1206–12.  https://doi.org/10.1097/MEG.0b013e32834cd6f6.CrossRefPubMedGoogle Scholar
  52. 52.
    Bansal RK, Kumar M, Sachdeva PR, Kumar A. Prospective study of profile of hepatic osteodystrophy in patients with non-choleastatic liver cirrhosis and impact of bisphosphonate supplementation. United European Gastroenterol J. 2016;4(1):77–83.  https://doi.org/10.1177/2050640615584535.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Mike T. Wei
    • 1
    • 2
  • Mindie H. Nguyen
    • 2
  • Ramsey Cheung
    • 2
    • 3
    Email author
  1. 1.Department of MedicineStanford UniversityPalo AltoUSA
  2. 2.Department of Medicine, Division of Gastroenterology and HepatologyStanford UniversityPalo AltoUSA
  3. 3.Division of Gastroenterology and HepatologyVeterans Affairs Palo Alto Health Care SystemPalo AltoUSA

Personalised recommendations